| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | ECL; SLC; CKb9; TCA4; 6Ckine; SCYA21 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CCL21 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CCL21抗体的3篇示例参考文献(需根据实际文献调整，建议通过数据库验证)：
---
1. **文献名称**：*CCL21-neutralizing antibody prevents dendritic cell migration and ameliorates experimental colitis*
**作者**：Yoshida R. et al.
**摘要**：研究通过中和CCL21抗体阻断树突状细胞向肠道淋巴结迁移，显著减轻小鼠结肠炎模型的炎症反应，提示CCL21在自身免疫疾病中的潜在治疗靶点。
2. **文献名称**：*Targeting CCL21/CCR7 axis in tumor-associated lymphatic remodeling inhibits metastasis*
**作者**：Liu Y. et al.
**摘要**：该文献利用CCL21抗体干扰肿瘤细胞与淋巴管内皮细胞的相互作用，发现可抑制乳腺癌模型中的淋巴转移，并重塑肿瘤微环境中的免疫抑制状态。
3. **文献名称**：*Anti-CCL21 therapy enhances T cell infiltration and synergizes with checkpoint inhibitors in solid tumors*
**作者**：Weber J.S. et al.
**摘要**：研究表明，CCL21抗体通过促进T细胞向肿瘤组织浸润，显著增强PD-1/PD-L1抑制剂的抗肿瘤效果，为联合免疫治疗提供了新策略。
---
**备注**：以上为示例，实际文献需通过PubMed、Web of Science等平台检索关键词(如“CCL21 antibody”或“CCL21 blockade”)。建议结合具体研究方向筛选近年高相关文献。
CCL21. a member of the CC chemokine family, is a small cytokine primarily produced by stromal cells in lymphoid tissues and endothelial cells. It plays a critical role in immune cell trafficking by binding to the CCR7 receptor, guiding dendritic cells, T cells, and other leukocytes to secondary lymphoid organs. This chemokine exists in two isoforms (CCL21a and CCL21b) with distinct C-terminal regions, influencing their localization and function. Dysregulation of CCL21 is implicated in autoimmune diseases, chronic inflammation, and cancer metastasis, particularly in lymph node dissemination.
CCL21 antibodies are essential tools for detecting and studying this chemokine’s expression, distribution, and mechanistic roles. They are widely used in techniques like immunohistochemistry, Western blotting, and flow cytometry to map CCL21 in tissues or assess its secretion in disease models. Neutralizing CCL21 antibodies can block CCR7-mediated signaling, enabling researchers to explore its contribution to immune responses or tumor microenvironments. In therapeutic contexts, anti-CCL21 strategies are being investigated to modulate immune cell recruitment in autoimmune disorders (e.g., rheumatoid arthritis) or inhibit cancer spread. Both monoclonal and polyclonal variants are available, with monoclonal antibodies offering higher specificity for targeted research. Recent studies also highlight CCL21’s role in lymphoid neogenesis and tertiary lymphoid structure formation, expanding its relevance in immunotherapy and vaccine development.
×
